CD4 and Opportunistic infection: Our study suggests that patients in later lines of therapy and patients receiving treatment with agents associated with further depletion of CD4+-T cells such as pomalidomide or carfilzomib might particularly benefit from prophylaxis against opportunistic infections.Also, determining CD4+-T-cell numbers before the initiation of relapse therapy may also help to better stratify patients requiring prophylaxis.